JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

430

Participants

Timeline

Start Date

January 15, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2027

Conditions

Ovarian CancerPrimary PeritonealFallopian Tube Cancers

Interventions

DRUG

JSKN003

Experimental drug

DRUG

Doxorubicin

Active Comparator

DRUG

Paclitaxel

Active Comparator

DRUG

Topotecan

Active Comparator

All Listed Sponsors

lead

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

INDUSTRY